HRAS and neoplasm: Among the 19 patients who developed benign tumours, only one (6%) carried somatic variant in KRAS, 16 (84%) showed a mutated HRAS allele, and two (10%) had mutations in PIK3CA genes; the 13 patients with cancer harboured somatic variants exclusively in the KRAS (31%) and HRAS (69%) genes.